Images |
Sources |
Experiment + Assay |
Phenotypes |
Human Diseases |
|
Fig 2 C abcd
Bou-Rouphael J et al. (2024)
|
Xla Wt + barhl1
NF45 (in situ hybridization)
|
|
|
|
Fig 3 A a' a""B C D a
Bou-Rouphael J et al. (2024)
|
Xla Wt + barhl1 MO
NF45 (in situ hybridization)
|
|
|
|
Fig. S3 D
Bou-Rouphael J et al. (2024)
|
Xla Wt + barhl1 MO
NF48 (in situ hybridization)
|
|
|
|
Fig 2 A a a' a'', b b' b'', c; B abcd
Bou-Rouphael J et al. (2024)
|
Xla wt +tcf7l1-delta_ctnnb1-GR
NF45 (in situ hybridization)
|
|
|
|
Fig. 2 A
Ismail T et al. (2024)
|
Xla Wt +PFOS
NF35/36 (in situ hybridization)
|
|
|
|
Fig. 3. B
O'Brien MP et al. (2023)
|
Xtr Wt + smc5 CRISPR
NF28 (in situ hybridization)
|
|
|
|
Fig. S3A r2c1-4
Job F et al. (2023)
|
Xla Wt + otud3 MO1/2
NF35/36 (in situ hybridization)
|
|
|
|
Fig.6.E-F
Hantel F et al. (2022)
|
Xla Wt + rmnd5a MO
NF32 (in situ hybridization)
|
|
microphthalmia
neural tube defect
|
No Image
|
Fig. 3CD
Flach H et al. (2022)
|
Xla Wt + glyphosate [121.5]
NF23 (in situ hybridization)
|
|
|
No Image
|
Fig. 3B
Flach H et al. (2022)
|
Xla Wt + glyphosate [243]
NF13 (in situ hybridization)
|
|
|